EClinicalMedicine
May 7, 2022
Hewa Artin, Sean Bentley, Eamonn Mehaffey et al.
35 citations
Summary: Background: (S)-ketamine is a glutamatergic drug with potent and rapid acting effects for the treatment of depression. Little is known about the effectiveness of intranasal (S)-ketamine for treating patients with comorbid depression and post-traumatic stress disorder (PTSD). Methods: We performed a retrospective case series analysis of clinical outcomes in 35 Veterans with co-morbid...
Frontiers in Behavioral Neuroscience
April 14, 2022
Shuai Yang, Ke Xu, Xuan Xu et al.
This study aims to explore the regulatory effect of S-ketamine on the mechanical allodynia, anxiety-like behaviors and microglia activation in adult male rats exposed to an animal model of post-traumatic stress disorder (PTSD). The rat PTSD model was established by the exposure to single-prolonged stress (SPS), and 1 day later, rats were intraperitoneally injected with 5 mg/kg S-ketamine or...
Canadian Journal of Health Technologies
April 12, 2022
Khai Tran, Quenby Mahood
Two randomized controlled trials reported mixed evidence on the efficacy of repeated IV ketamine infusions for improving post-traumatic stress disorder. One randomized controlled trial with small sample size found that repeated IV ketamine infusions significantly improved post-traumatic stress disorder symptoms compared with midazolam in civilian population, while the other randomized...
Frontiers in Psychiatry
March 9, 2022
Rui Du, Ruili Han, Kun Wang Niu et al.
42 citations
Background Post-traumatic stress disorder (PTSD) is a serious stress-related disorder caused by traumatic experiences. However, identifying a key therapy that can be used for PTSD treatment remains difficult. Ketamine, a well-known dissociative anesthetic, is considered safe to be used in anesthesia, pain management, and antidepressant actions since 1970. At present, it is still controversial...
Molecular and cellular neurosciences
March 1, 2022
Muhammad Asim, B. Hao, Abdul Waris et al.
Post-traumatic stress disorder (PTSD) is a devastating mental illness with high morbidity and major social and economic burden. Currently, there is no promising therapy available for the treatment of PTSD. Some clinical studies showed that ketamine could effectively alleviate PTSD symptoms. However, it is still unclear which brain region ketamine targets and how it attenuates the PTSD-like...
Pharmacotherapy
February 5, 2022
Sean Bentley, Hewa Artin, Eamonn Mehaffey et al.
Racemic (R,S)‐ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)‐ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment‐resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of...
Frontiers in Psychiatry
January 12, 2022
Shannon Dames, Pamela Kryskow, Crosbie Watler
38 citations
Amid an international pandemic and a worsening mental health crisis, ketamine-assisted therapy is emerging as a promising solution for those deemed “treatment resistant.” Post-traumatic stress disorder (PTSD) and depression are on the rise, with accelerating direct (e.g., burden of suffering) and indirect (e.g., disability/role impairment and impact on family) costs. Psychedelic-assisted...
Frontiers in Psychiatry
2022
Shannon Dames, Pamela Kryskow, Crosbie Watler
correction
Corrigendum: A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers with PTSD and DepressionError in Figure/TableIn the published article, there was an error in Figure 2 as published. The PTSD label on the legend that is imbedded in the figure was on the legend component of the figure was posted on the anxiety...
Frontiers in Psychiatry
2022
Joshua Willms, Ben McCauley, Lindsay Kerr et al.
Suicide is the most common cause of death in male resident physicians and the second most common cause of death in resident physicians overall. Physicians also experience high rates of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and burnout. These conditions frequently develop during medical school, and threaten not only physicians but the patients they care for. A...
Clinical Case Studies
August 1, 2021
Mailae Halstead, Sara Reed, Robert Krause et al.
Current research suggests that ketamine-assisted psychotherapy has benefit for the treatment of mental disorders. We report on the results of ketamine-assisted intensive outpatient psychotherapeutic treatment of a client with treatment-resistant, posttraumatic stress disorder (PTSD) as a result of experiences of racism and childhood sexual abuse. The client’s presenting symptoms included...